Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Highlights this week included:

UK: The Synthia saga: CIPA fights back – synthetic life forms patentability (IPKat) (IPKat) (PatLit) (Tangible IP)

GSK promotes open innovation by sharing malaria inhibitor compounds (Patent Docs) (Afro-IP)

General

World Health Assembly: Latest chair’s draft issued on future of WHO and IP, innovation (IP Watch)

World Health Assembly: WHO’s precious Matsoso on public health, innovation and intellectual property (IP Watch)

WHO: No evidence of misleading on counterfeit medicines (IP Watch)

Debate erupts over WHO police work against ‘counterfeit’ drugs trade (IP Watch)

NGOs, industry weigh alternatives for R&D financing, counterfeiting at WHO (IP Watch)

New resolution gives governments control of WHO work on false medicines (IP Watch) (IP Watch)

CII roundtable on proposed Anti-Counterfeiting Trade Agreement (ACTA) and TRIPS (Generic Pharmaceuticals and IP)

Global health progress/IFPMA fete African health ministers in Geneva on public private partnerships (Knowledge Ecology International)

Marks & Clerk survey predicts rise in consolidation as Biotech/Pharma industry nears patent cliff (Patent Docs)

GSK promotes open innovation by sharing malaria inhibitor compounds (Patent Docs) (Afro-IP)

IP can support Biodiversity (WIPO)

Regional and global policies – access to medicines (IP tango)

Colombia: UN addressed Colombia in IP matters (IP tango)

EU: Infringement of SPCs by combination products (SPC blog)

India: An inert patent? (Spicy IP)

Kenya: Suspension of Anti Counterfeiting Act: Patricia Asero Ochieng’, Maurine Atieno and Joseph Munyi v The Republic (Afro-IP)

Kenya: Origins of Kenya’s controversial Anti Counterfeiting Act (Afro-IP)

UK: The Synthia saga: CIPA fights back – synthetic life forms patentability (IPKat) (IPKat) (PatLit) (Tangible IP)

US: USPTO continues to modify system for calculating PTA; in view of Wyeth (Patent Docs)

US: Novozymes files patent infringement suit against Danisco and others based on manufacture and sale of alpha amylase products (Patent Docs)

US: Dr George Pieczenik files complaints against numerous pharma companies over alleged infringement of patent covering ‘Method and means for sorting and identifying biological information’: Pieczenik v. Idexx Reference Laboratories, Inc. et al.; Pieczenik v. AstraZeneca Pharmaceuticals LP et al. (Patent Docs)

US: Genetic Technologies’ patent in suit against Monsanto and Pioneer Hi-Bred upheld on re-examination (Patent Docs)

Products

Angiomax (Bivalirudin) – US: Court orders and PTO grants second interim PTE for Angiomax (FDA Law Blog)

Cancidas (Caspofungin) – US: Patent infringement complaint following Para IV certification: Merck & Co, Inc. et al. v. Sandoz Inc. (Patent Docs)

Cialis: (Tadalafil) – US: CAFC: Appellant fails to prove inventorship: Vanderbilt Univ. v. ICOS Corp. (Patent Docs)

Cipro (Ciprofloxacin)- Cipro patent settlement case appealed to the California Court of Appeal: In re Ciprofloxacin Antitrust Litigation (FDA Law Blog) (Patent Docs)

Fluvastatin – Spain: Interim injunctive relief in Spain – Novartis (PatLit)

Intuniv (Guanfacine) – US: Patent infringement complaint based on ANDA filing: Shire LLC et al. v. Actavis Elizabeth LLC et al. (Patent Docs)

Levaquin (Levofloxacin) – US: When it comes to patent term extensions, an enantiomer is a different drug from racemate: Ortho-McNeil Pharma v. Lupin Pharma (Patent Baristas)

Metvixia (Methyl aminolevulinate) – US: Structurally similar drug with different biological properties meets criteria for term extension: Photocure ASA v Kappos (Patent Baristas)

Mirapex (Pramipexole) – US: Patent infringement complaint based on ANDA filing: Sandoz Inc. v. Boehringer Ingelheim International GMBH et al. (Patent Docs)

PrandiMet (Repaglinide and Metformin) – US: Infringement of patent following Paragraph IV certification: Novo Nordisk Inc. et al. v. Lupin Ltd. (Patent Docs)

Restoril (Temazepam) – US: District Court New Jersey: Covidien’s patent for Restoril found obvious: Tyco Healthcare v Mutual Pharmaceutical Company (Patent Docs)

Seroquel (Quetiapine) – US: Patent infringement complaint following Paragraph IV challenge: AstraZeneca Pharmaceuticals LP et al. v. Anchen Pharmaceuticals Inc et al. (Patent Docs)

Tarceva (Erlotinib) – India: Roche-Natco update: ‘Public interest’ again? (Spicy IP)

Trilipix (Fenofibrate) – US: Patent infringement complaint following Paragraph IV challenge: Abbott Laboratories et al. v. Actavis Elizabeth LLC et al. (Patent Docs)

Valcyte (Valganciclovir) – India: Raising the bar for post-grant oppositions: Lessons on procedure and evidence post the Valcyte ‘post-grant opposition’ (Spicy IP) (Spicy IP) (Spicy IP)

Vanos (Fluocinonide) – US: Patent infringement complaint following Paragraph IV challenge: Medicis Pharmaceutical Corp. v. Nycomed US Inc. et al. (Patent Docs)

Zetia (Ezetimibe) – US: Merck and Glenmark settle Zetia patent suit (Patent Docs)